Home / Business and Economy / Cancer Trial Shows Extended Survival, Funds Secured
Cancer Trial Shows Extended Survival, Funds Secured
4 Sep
Summary
- Phase 3 liver cancer trial shows longer survival trends.
- Warrant exercise agreement secures $4 million in funding.
- Company considers earlier interim analysis for the trial.
Can-Fite BioPharma Ltd. has reported encouraging results from its Phase 3 trial for Namodenoson in advanced hepatocellular carcinoma (HCC). The trial, focusing on patients with Child-Pugh B7 cirrhosis, has observed longer-than-anticipated overall survival rates in a blinded analysis.
This positive development has prompted management to evaluate an earlier timeline for the study's interim analysis. Concurrently, the company announced a $4 million warrant exercise agreement, providing crucial funding for continued clinical development and general corporate activities.
The financial agreement involves the exercise of warrants originally issued in March 2026, with a revised exercise price of $2.50 per American Depositary Share (ADS). This transaction is expected to bolster the company's resources for research, clinical trials, and operational needs.
